Group 1 - The company has not declared any cash dividends or bonus shares during the reporting period [3] - The company received several approvals from the National Medical Products Administration for its products, including sodium hyaluronate eye drops and antiviral tablets [5] - The company held its eighth board meeting on August 14, 2025, where various reports and proposals were approved [40][41] Group 2 - The company reported a total fundraising amount of RMB 455.53 million from its initial public offering, with a net amount of RMB 390.93 million after expenses [27][28] - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests [30] - As of June 30, 2025, the company has used RMB 44.55 million of its excess fundraising to permanently supplement its working capital [33][35] Group 3 - The company plans to hold its first extraordinary general meeting of 2025 on September 2, 2025, to discuss various proposals [8][52] - The meeting will allow shareholders to vote both in person and online, ensuring accessibility for all stakeholders [9][10] - The company has made amendments to its internal management systems to enhance operational efficiency and compliance with legal requirements [7][50]
吉林省西点药业科技发展股份有限公司2025年半年度报告摘要